Akkermansia muciniphila in Inflammatory Bowel Disease and Colorectal Cancer

0
0
0

Akkermansia muciniphila in Inflammatory Bowel Disease and Colorectal Cancer

Did you know that a single type of gut bacteria—Akkermansia muciniphila—might hold clues to treating two of the most common intestinal diseases: inflammatory bowel disease (IBD) and colorectal cancer (CRC)? For years, scientists have studied how imbalances in gut bacteria (called dysbiosis) contribute to these conditions. Now, research from Zhen-Yang Gu, Wen-Long Pei, Yi Zhang, Jun Zhu, Lei Li, and Zhan Zhang at the Center for Global Health, School of Public Health, Nanjing Medical University, suggests that A. muciniphila—a unique bacterium that feeds on gut mucus—could be both a biomarker and a potential target for treatment. Let’s break down what we know.

What Is Akkermansia muciniphila?

A. muciniphila is a Gram-negative anaerobic bacterium first isolated in 2004 from the feces of a healthy Caucasian woman at Wageningen University. By age 1, it stably colonizes the human gut, making up 1–4% of the total gut microbiota. Its defining trait? It specializes in breaking down mucin—the glycoprotein that forms the protective mucus layer lining your intestines. Unlike harmful bacteria that invade the inner mucus layer, A. muciniphila stays in the outer layer and doesn’t cause disease. In fact, recent studies show it helps maintain gut homeostasis—the balance of your intestinal ecosystem.

A. muciniphila in IBD and CRC: The Research So Far

Dysbiosis is a hallmark of IBD (which includes ulcerative colitis (UC) and Crohn’s disease (CD)) and CRC, especially colitis-associated CRC (CAC). The Nanjing Medical University team found that A. muciniphila is less abundant in people with UC and CD—and in mice with experimental colitis induced by chemicals like dextran sulfate sodium (DSS) or 2,4,6-trinitrobenzenesulfonic acid (TNBS). In CAC (caused by a combination of the carcinogen azoxymethane (AOM) and DSS), A. muciniphila levels drop even more, while harmful bacteria like Desulfovibrio and Helicobacter rise. What’s more, lower A. muciniphila in colon biopsies correlates with higher levels of trimethylamine N-oxide (TMAO)—a molecule linked to CRC risk.

But here’s the twist: Some studies show higher A. muciniphila in CRC patients or in mice prone to colitis (like those missing the anti-inflammatory protein IL-10). Why the conflict? The researchers think factors like disease activity, genetic makeup, and overall health status play a role. More large-scale human studies and clinical trials are needed to confirm the link.

Diet, Probiotics, and Medications—How They Impact A. muciniphila

Your lifestyle choices directly shape your gut microbiota—and A. muciniphila is no exception. Here’s how three key factors influence it:

Diet

Diet is one of the most powerful ways to modulate gut bacteria. The Nanjing team found that:

  • Ketogenic diets reduce colitis by increasing A. muciniphila and lowering pro-inflammatory immune cells (group 3 innate lymphoid cells).
  • Fermented foods protect against colitis induced by pathogenic bacteria or DSS by boosting A. muciniphila.
  • Phytochemicals (plant compounds like caffeic acid derivatives, myricetin, resveratrol, and teasaponin) increase A. muciniphila and ease colitis in mice.

But not all “healthy” foods work the same way. Barley leaf insoluble fiber and egg white peptides help colitis—but they actually reduce A. muciniphila. Host-derived substances (like primary/secondary bile acids, vitamin D, and α-ketoglutarate) also boost A. muciniphila and protect against colitis/CRC by strengthening gut barrier integrity and regulating the immune system.

Probiotics

Probiotics—live bacteria that promote gut health—are increasingly used to treat IBD and CRC. Single strains like Lactobacillus pentosus reduce colitis symptoms by increasing A. muciniphila and short-chain fatty acids (SCFAs)—compounds that feed gut cells and reduce inflammation. Mixed probiotics (e.g., Bifidobacterium infantis, Lactobacillus acidophilus, Enterococcus faecalis, Bacillus cereus) rebuild the gut microbiota in DSS-induced colitis, increasing A. muciniphila, Bifidobacterium, and Lactobacillus. Some probiotics even work with plant extracts to shrink tumors in CAC mice—again, by boosting A. muciniphila.

But here’s the catch: Some probiotics lower A. muciniphila while still reducing inflammation. Effectiveness depends on the probiotic species and the disease—probiotics are not one-size-fits-all.

Medications

The interaction between gut microbes and drugs is complex, but A. muciniphila often plays a role. For example:

  • Metformin (a diabetes drug) alleviates colitis in mice by increasing A. muciniphila.
  • TAK-242 (a TLR4 inhibitor) helps UC by promoting A. muciniphila growth.
  • Hyaluronic acid-bilirubin nanomedicine enriches A. muciniphila and regulates innate immunity to treat colitis.
  • MS-444 (a HuR inhibitor) increases A. muciniphila and reduces tumor growth in a CRC mouse model (APCMin/+).

Even traditional Chinese medicines like berberine or alisol B 23-acetate affect A. muciniphila—though berberine lowers it while still preventing CAC. The takeaway? A. muciniphila can act as a middleman for drug effects on IBD and CRC.

Can A. muciniphila Be Used as a Treatment?

Emerging evidence says yes—with caveats. The Nanjing team and others found that giving A. muciniphila (strain DSM 22959) to mice on a casein diet accelerated colitis recovery: It reduced disease severity, thickened the mucus layer, and increased muc2 (a key mucus protein) production. The type strain ATCC BAA-835 also eases DSS-induced colitis by improving microbe-host interactions. Even a murine strain (designated 139) has anti-inflammatory effects—though ATCC BAA-835 works better, highlighting the importance of strain differences.

But you don’t need live bacteria to see benefits. Pasteurized A. muciniphila (ATCC BAA-835) and Amuc_1100 (a protein from its outer membrane) blunt CAC in mice by expanding CD8+ T cells, which kill cancer cells. A. muciniphila-derived extracellular vesicles also strengthen gut tight junctions (the “seal” between intestinal cells), reducing leakiness. And oral A. muciniphila increases anti-aging and anti-cancer metabolites like SCFAs, polyamines, and bile acids—effects that are stronger with pasteurized bacteria than live ones.

But wait: A. muciniphila isn’t always a hero. In mice missing IL-10 (a model of severe colitis), repeated doses of ATCC BAA-835 can cause spontaneous colitis. That means in people with certain genetic vulnerabilities, A. muciniphila might act as a “pathobiont”—a normally harmless bacterium that becomes harmful under stress. The researchers warn that genetic makeup and disease state must be considered before using A. muciniphila as a therapy.

Conclusion

So, is A. muciniphila a friend or foe? The answer is: It depends. For most people, higher A. muciniphila is linked to protection against IBD and CRC—especially when boosted by diet, probiotics, or medications. But in some genetic contexts, it can worsen colitis. What’s clear is that A. muciniphila is a key player in gut health—and its potential as a therapy is exciting. The Nanjing team’s work suggests that A. muciniphila, its proteins (like Amuc_1100), or its extracellular vesicles could one day be used to prevent or treat intestinal diseases. But first, we need more research to understand strain differences, genetic interactions, and long-term effects.

For now, the takeaway is simple: Your gut microbiota—including A. muciniphila—plays a bigger role in your health than you might think. And the foods you eat, the probiotics you take, and even the drugs you use could all influence whether this tiny bacterium works for you or against you.

This article is based on research by Zhen-Yang Gu, Wen-Long Pei, Yi Zhang, Jun Zhu, Lei Li, and Zhan Zhang from the Center for Global Health, School of Public Health, Nanjing Medical University, published in the Chinese Medical Journal in 2021.

References:

  1. Zhou JC, Zhang XW. Akkermansia muciniphila: a promising target for the therapy of metabolic syndrome and related diseases. Chin J Nat Med 2019;17:835–841. doi.org/10.1016/S1875-5364(19)30101-3
  2. Derrien M, Van Baarlen P, Hooiveld G, Norin E, Muller M, de Vos WM. Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the Mucin-Degrader Akkermansia muciniphila. Front Microbiol 2011;2:166. doi.org/10.3389/fmicb.2011.00166
  3. Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 2019;25:1096–1103. doi.org/10.1038/s41591-019-0495-2
  4. Yoon HS, Cho CH, Yun MS, Jang SJ, You HJ, Kim JH, et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nat Microbiol 2021;6:563–573. doi.org/10.1038/s41564-021-00880-5
  5. Zhang T, Li P, Wu X, Lu G, Marcella C, Ji X, et al. Alterations of Akkermansia muciniphila in the inflammatory bowel disease patients with washed microbiota transplantation. Appl Microbiol Biotechnol 2020;104:10203–10215. doi.org/10.1007/s00253-020-10948-7
  6. Zhang T, Ji X, Lu G, Zhang F. The potential of Akkermansia muciniphila in inflammatory bowel disease. Appl Microbiol Biotechnol 2021;105:5785–5794. doi.org/10.1007/s00253-021-11453-1
  7. Griffin LE, Djuric Z, Angiletta CJ, Mitchell CM, Baugh ME, Davy KP, et al. A Mediterranean diet does not alter plasma trimethylamine N-oxide concentrations in healthy adults at risk for colon cancer. Food Funct 2019;10:2138–2147. doi.org/10.1039/c9fo00333a
  8. Wang L, Tang L, Feng Y, Zhao S, Han M, Zhang C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8(+) T cells in mice. Gut 2020;69:1988–1997. doi.org/10.1136/gutjnl-2019-320105
  9. Chen Y, Zhang L, Hong G, Huang C, Qian W, Bai T, et al. Probiotic mixtures with aerobic constituent promoted the recovery of multi-barriers in DSS-induced chronic colitis. Life Sci 2020;240:117089. doi.org/10.1016/j.lfs.2019.117089
  10. Fan L, Qi Y, Qu S, Chen X, Li A, Hendi M, et al. B. adolescentis ameliorates chronic colitis by regulating Treg/Th2 response and gut microbiota remodeling. Gut Microbes 2021;13:1–17. doi.org/10.1080/19490976.2020.1826746
  11. Liu Z, Liao W, Zhang Z, Sun R, Luo Y, Chen Q, et al. Metformin affects gut microbiota composition and diversity associated with amelioration of dextran sulfate sodium-induced colitis in mice. Front Pharmacol 2021;12:640347. doi.org/10.3389/fphar.2021.640347
  12. Yu L, Zhao D, Nian Y, Li C. Casein-fed mice showed faster recovery from DSS-induced colitis than chicken-protein-fed mice. Food Funct 2021;12:5806–5820. doi.org/10.1039/d1fo00659b
  13. Bian X, Wu W, Yang L, Lv L, Wang Q, Li Y, et al. Administration of Akkermansia muciniphila ameliorates dextran sulfate sodium-induced ulcerative colitis in mice. Front Microbiol 2019;10:2259. doi.org/10.3389/fmicb.2019.02259
  14. Zhai R, Xue X, Zhang L, Yang X, Zhao L, Zhang C. Strain-specific anti-inflammatory properties of two Akkermansia muciniphila strains on chronic colitis in mice. Front Cell Infect Microbiol 2019;9:239. doi.org/10.3389/fcimb.2019.00239
  15. Kim Y, Hwang SW, Kim S, Lee YS, Kim TY, Lee SH, et al. Dietary cellulose prevents gut inflammation by modulating lipid metabolism and gut microbiota. Gut Microbes 2020;11:944–961. doi.org/10.1080/19490976.2020.1730149
  16. Chelakkot C, Choi Y, Kim DK, Park HT, Ghim J, Kwon Y, et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp Mol Med 2018;50:e450. doi.org/10.1038/emm.2017.282
  17. Seregin SS, Golovchenko N, Schaf B, Chen J, Pudlo NA, Mitchell J, et al. NLRP6 protects Il10(−/−) mice from colitis by limiting colonization of Akkermansia muciniphila. Cell Rep 2017;19:733–745. doi.org/10.1016/j.celrep.2017.03.080

Was this helpful?

0 / 0